Merck Eyes Emerging Biosimilars Market In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
The company's Japanese subsidiary Banyu Pharmaceutical has started domestic trials for its generic erythropoietin, poised to be Merck's first biosimilar launch.